Publications by authors named "Rebecca Yelton"
Article Synopsis
- The study explores access to CART19 immunotherapy for large B-cell lymphomas among minority health populations (MHPs) compared to non-MHPs in different hospital settings.
- It found that while MHPs had access to care for LBCL, their representation in CART19 therapy was lower, with only 6.7% at the Abramson Cancer Center and 4.2% at the Knight Cancer Institute receiving the treatment.
- Outcomes for MHPs who did receive CART19 were similar to non-MHPs regarding response and survival, but the small sample size necessitates further research to confirm these findings.
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy of bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD before CD19-directed, CD28-costimulated CART axicabtagene ciloleucel (axi-cel) for patients with large B-cell lymphoma (LBCL) and follicular lymphoma (FL). We analyzed 59 patients diagnosed with LBCL (n = 48) and FL (n = 11) consecutively treated with axi-cel at the University of Pennsylvania.
View Article and Find Full Text PDF